Article Text

other Versions

PDF
Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial
  1. Ryoichi Hamasuna1,2,3,
  2. Satoshi Takahashi2,4,
  3. Hiroshi Kiyota2,5,
  4. Mitsuru Yasuda2,6,
  5. Hiroshi Hayami2,7,
  6. Soichi Arakawa2,8,
  7. Kazunori Tomono9,
  8. Tetsuro Matsumoto1,2
  1. 1Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
  2. 2Japanese research group for UTI, Japan
  3. 3Department of Urology, Faculty of Medicine, Miyazaki University, Miyazaki, Japan
  4. 4Department of Urology, Sapporo Medical University, Sapporo, Japan
  5. 5Department of Urology, Jikei University Affiliated Aoto Hospital, Tokyo, Japan
  6. 6Department of Urology, School of Medicine, Gifu University, Gifu, Japan
  7. 7Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan
  8. 8Division of Integrated Medical Education, Department of Social/Community Medical and Health Science, Kobe University Graduate School of Medicine, Kobe, Japan
  9. 9Infection Control Team, Osaka University Hospital, Osaka, Japan
  1. Correspondence to Ryoichi Hamasuna, Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan; hamaryo{at}med.uoeh-u.ac.jp

Abstract

Objectives Mycoplasma genitalium and Chlamydia trachomatis are the primary pathogens detected from non-gonococcal urethritis (NGU). In this study, the efficacy of gatifloxacin was examined against M genitalium-related urethritis.

Methods The study was an open clinical trial evaluating the effectiveness of gatifloxacin with 200 mg doses twice a day for 7 days against male NGU.

Results Between March and September 2008, 169 male patients were enrolled, and microbiological and clinical cure rates could be evaluated in 86 patients detected with C trachomatis or M genitalium and in 135 with NGU, respectively. Microbiological cure rates of gatifloxacin against C trachomatis and M genitalium were 100% and 83%, respectively, and the total clinical cure rate was 99%.

Conclusion Analysis of in-vivo and in-vitro data from the literature of fluoroquinolone efficacies against M genitalium suggests that a MIC90 of 0.125 μg/ml or less may be useful for optimal activity against M genitalium infection.

  • Antibiotics
  • clinical trials
  • mycoplasma
  • NGU

Statistics from Altmetric.com

Footnotes

  • Funding This study received funding from the Supporting Center for Clinical Research and Education (SCCRE), Osaka, Japan.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the ethics committee of Osaka University, Osaka, Japan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.